ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

pelabresib

Also written as “Pelabresib” and “CPI-0610”.

In Novartis’s pipeline, BET inhibitor. Its studies are mostly in Primary Myelofibrosis · Hematologic Neoplasms · Lymphoma, Follicular · Lymphoma · Multiple Myeloma, led by 2 companies.

Drug pageCPI-0610: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 20, 202011 company-led studies, 7 open or runningAcquisition: Novartis acquired MorphoSys, May 2024Next primary completion: Mar 9, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartisits history only77 open or runningphase 3since Oct 20, 2020Oct 20, 2020Mar 9, 2028phase 1 · NCT07340190
Constellation Pharmaceuticals40 open or runningphase 2since Jun 5, 2014Sep 10, 2013none ahead
  • Named in Novartis’s own pipeline as DAK539 (pelabresib), phase 4, as of Nov 16, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Constellation Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 10, 2013First study: phase 1 study in LymphomaFirst studyNCT01949883 · 64 enrolled
  2. May 28, 2014Phase 1 study in Multiple MyelomaNCT02157636 · 30 enrolled
  3. Jun 5, 2014Phase 2 study in Primary MyelofibrosisNCT02158858 · 336 enrolled · United States, Belgium, Canada and more
  4. Jun 9, 2020Named pelabresibINNProposed as its International Nonproprietary Name in WHO's List 123 · before, CPI-0610
  5. Jul 15, 2021MorphoSys acquired Constellation PharmaceuticalsAcquisitionWith it pelabresib (CPI-0610) · completed · MorphoSys (release filed with the SEC)
  6. May 5, 2022Phase 1 study in Hematologic NeoplasmsNCT05391022 · 35 enrolled · United States, Georgia, Spain
  7. May 2024Novartis acquired MorphoSysAcquisitionWith it pelabresib, which MorphoSys held · completed · Novartis

TargetBeta

“BET inhibitor”the company's pipeline, read by Claude · source
“The hydrated form of pelabresib, a small molecule inhibitor of the Bromodomain and Extra-Terminal (BET) family of proteins, with potential antineoplastic activity. Upon administration, pelabresib binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, thereby prevent…”NCIt, read by Claude
“Bromodomain and extra-terminal motif (BET) inhibitor”ChEMBL 37, by rule

Studies

All 4 Constellation Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05391022Hematologic Neoplasms · United States, Georgia, Spain1CompletedMar 8, 202335
NCT02158858Primary Myelofibrosis · United States, Belgium, Canada and more2CompletedJan 9, 2025336
NCT02157636Multiple Myeloma1CompletedNov 8, 201630
NCT01949883Lymphoma1CompletedDec 20, 201764

How it is read

Names in the registry

  • “Pelabresib”, 7 entries
  • “pelabresib”, 2 entries
  • “CPI-0610”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.